3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
11
NETWORK
3
NIH
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
199
Breast Neoplasms
136
Prostatic Neoplasms
72
Neoplasms
62
Neoplasm Metastasis
52
Lung Neoplasms
45
Stomach Neoplasms
27
Parkinson Disease 4, Autosomal Dominant Lewy Body
22
Squamous Cell Carcinoma of Head and Neck
17
Ovarian Neoplasms
15
Advanced Solid Tumors
14
Recurrence
12
Head and Neck Neoplasms
11
Colorectal Neoplasms
11
Carcinoma, Squamous Cell
11
Urinary Bladder Neoplasms
10
Melanoma
10
Esophageal Neoplasms
10
HER2-positive Breast Cancer
9
Endometrial Neoplasms
9
Carcinoma, Renal Cell
9
Sarcoma
8
Esophageal Squamous Cell Carcinoma
8
Carcinoma, Transitional Cell
8
Solid Tumor
7
Prostatic Neoplasms, Castration-Resistant
7
Pancreatic Neoplasms
7
Carcinoma
7
Triple Negative Breast Neoplasms
6
Small Cell Lung Carcinoma
6
Interventions
pembrolizumab
3
entrectinib
2
zanidatamab
1
trastuzumab deruxtecan
1
spartalizumab
1
neratinib
1
larotrectinib
1
cevimeline
1
apalutamide
1
alectinib
1
Tablets
1
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Immunotherapy
1
Gonadotropin-Releasing Hormone
1
Fentanyl
1
EBC-46
1
Drug Therapy
1
Docetaxel
1
Combined Modality Therapy
1
Carboplatin
1
Biological Therapy
1
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Salivary Gland Neoplasms
×
Docetaxel
×
Clear all
NCT04140526
2025-05-23
PRESERVE-001
OncoC4, Inc.
Phase 1/2
Active not recruiting
733 enrolled